U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining around 200 points on Tuesday.
The Dow traded up 0.53% to 37,505.25 while the NASDAQ rose 0.51% to 14,980.71. The S&P 500 also rose, gaining, 0.45% to 4,762.12.
Kronos Bio Inc (NASDAQ: KRON) says that after the review of data from the phase 1b portion of its phase 1b/2 trial of lanraplenib in combination with gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia (AML), the company has decided not to
Piper Sandler analyst Kashy Harrison revised the rating on several Renewables & Alternative Energy companies.
The analyst sees benefits accruing to the installers initially (FY24) and inverters eventually (FY25), with the rest of the stock in the coverage benefiting in the long term.
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with the company to exclusively license its novel pre-clinical immunotherapy program.
Compugen shares jumped 204.1% to $2.22 on Tuesday.
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 150 points on Tuesday.
The Dow traded up 0.46% to 37,476.21 while the NASDAQ rose 0.41% to 14,966.74. The S&P 500 also rose, gaining, 0.38% to 4,758.55.